DNA vaccines are an alternative immunisation model involving the transfection of mammalian cells in vivo allowing a host to express antigenic protein against which it may raise an immune response. There are some issues preventing the wide application of DNA vaccines, including the stability of naked plasmid DNA in vivo. One proposed solution is the application of nanoparticle technology as a vaccine delivery platform. In this study, novel adjuvanted solid lipid nanoparticles (SLN) were synthesised as a DNA vaccine delivery system. Synthesised SLN’s of approximately 100 nm in size were optimised for a strongly cationic surface charge to enable surface binding of plasmid DNA. A plasmid DNA vaccine vector was designed to express the Urease alpha antigen of Helicobacter pylori, and lipid particle/plasmid lipoplexes were synthesised and characterised. The vaccine complex was found to be non-cytotoxic and was readily taken up by immune cells in vitro. The vaccine antigen was found to be expressed by both epithelial and dendritic cell lines in vitro at higher rates than naked plasmid alone. The results of this study indicate that adjuvanted SLN’s may improve DNA vaccine uptake and expression, and further animal studies will determine the efficacy of this platform in vivo.